AI is being deployed to catch diagnostic patterns in women's health that human doctors routinely miss, from heart disease to rare genetic disorders, while simultaneously addressing a decades-long data gap that has left female patients underrepresented in drug discovery. The convergence of these two shifts, discussed at the HLTH Europe 2026 conference and demonstrated in recent clinical deployments, represents a fundamental reckoning with how healthcare has historically treated women's biology as an afterthought.

Why Are Women's Health Diagnoses So Often Delayed or Wrong?

The numbers tell a stark story. When a woman has a heart attack, she is twice as likely as a man to be misdiagnosed or dismissed. Women with endometriosis, a condition as common as type 2 diabetes, routinely wait 5 to 10 years for a diagnosis, with surgery remaining the only definitive way to confirm the disease. Anxiety disorders, the most common mental health conditions worldwide, affect women at twice the rate of men, yet the healthcare system frequently overlooks them.

The root cause is not negligence but rather a fundamental mismatch between how diseases present in women's bodies and what clinicians are trained to recognize. Male cardiac events typically show up as blockages in the main arteries, easily spotted on standard chest pain protocols. Female cardiac pathology, by contrast, often manifests as coronary microvascular dysfunction in the smaller vessels surrounding the heart. Because human eyes looking strictly for main arterial blockages routinely miss these subtle dysfunctions, clinicians require augmenting AI to flag patterns that would otherwise be overlooked.

How Are AI Tools Being Deployed to Fix This?

Healthcare leaders are implementing AI across three distinct clinical functions. Amira Romani, senior vice president of global innovation and technology at Siemens Healthineers, outlined the framework:

• Assisting: Driving workflow efficiency for standard clinical reads, freeing physicians from routine administrative tasks.
• Augmenting: Overcoming historic clinical blind spots by identifying female-specific pathology patterns that traditional diagnostic criteria overlook.
• Expanding: Delivering specialist-level diagnostic capabilities to rural and underserved regions lacking direct access to expert care.

One emerging tool is ambient listening technology, which captures clinical summaries automatically and allows physicians to focus directly on patients, improving rapport and building clinical trust while gathering necessary longitudinal data.

In practice, this means novel algorithms are already utilizing existing mammography infrastructure to scan for breast arterial calcification, a strong indicator of microvascular hardening that escalates cardiovascular risk during perimenopause. As Romani noted, "The technology is there, we just need to use it".

As Romani

What Role Is Better Data Playing in Drug Discovery?

The second half of the women's health equation involves data. Machine learning algorithms have successfully condensed traditional drug discovery timelines from over four years down to just 13 months, according to Petrina Kamya, global head of AI platforms at Insilico Medicine. But these models are entirely dependent on their training data.

"If you're missing out on over 50% of patients because the data used to train a model is not catering to them, it's going to be a problem for your ROI and your patients," Kamya warned.

Petrina Kamya, Global Head of AI Platforms at Insilico Medicine

Overcoming this data deficit requires a transition to multimodal, longitudinal data aggregation. By combining traditional medical imaging with wearable metrics and omics data (genetic and molecular information), researchers can identify non-invasive biomarkers that reflect how diseases actually present in women's bodies.

Why Is Investment in Women's Health Still So Low?

Despite the clinical urgency, the financial infrastructure supporting female-focused healthcare remains disproportionately lean. Women's health captures only about 6% of private healthcare investment, according to Helen Gaffney, principal of investments at Novo Holdings. Historically, the bulk of this capital has clustered around a narrow selection of well-understood indications, such as breast cancer and fertility interventions.

However, a significant demand signal is beginning to bridge this gap. Two of the top 10 global pharmaceutical companies have recently entered the endometriosis pipeline, providing a powerful incentive for early-stage capital to flow into women's health startups. Breaking the chicken-and-egg cycle between early-stage and late-stage investment requires establishing robust therapeutic markets, and the pharmaceutical industry's recent moves suggest that market is finally forming.

How Can Healthcare Systems Implement These AI Solutions?

• Integrate Ambient Listening: Deploy automatic clinical note-taking systems to reduce administrative burden on physicians and capture longitudinal patient data that can feed into AI diagnostic tools.
• Audit Diagnostic Protocols: Review existing clinical guidelines to identify where female-specific disease presentations are missing, then pair human clinicians with AI augmentation tools to catch those patterns.
• Expand Data Collection: Move beyond traditional medical imaging to include wearable data and molecular biomarkers, ensuring that AI training datasets reflect the full diversity of how diseases present across different populations.
• Deploy AI to Underserved Regions: Use AI-driven diagnostic tools in primary care clinics in rural or underserved areas to place specialist-level screening capabilities into the hands of providers who lack access to cardiologists, geneticists, or other specialists.

The conversation around women's health is expanding far beyond reproductive care, moving toward a holistic, life-course approach to tackle systemic diagnostic delays, data fragmentation, and biological biases across multiple therapeutic areas. As Mare Lensvelt, editor-in-chief at Dutch Health Hub, noted, "The conversation is slowly evolving," but clinical leaders emphasize that awareness-raising is only the first step.

The real test will be whether healthcare systems and pharmaceutical companies can sustain the momentum. AI tools are now available to catch what human clinicians miss, and better data is flowing into drug discovery pipelines. What remains is the harder work of changing how medicine is practiced and funded to ensure that women's health is no longer an afterthought.